Efficacy of the spatial repellent product Mosquito Shield™ against wild pyrethroid-resistant <em>Anopheles arabiensis</em> in south-eastern Tanzania (Publications)
active ingredient (AI) within a space offer a scalable solution to further reduce transmission of malaria, by disrupting mosquito behaviours in ways that ultimately lead to reduced human-vector contact.
Immune system development varies according to age, location, and anemia in African children (Publications)
Mozambique by detailed immunophenotyping of longitudinal blood samples collected during the RTS,S malaria vaccine phase 3 trial. In these cohorts, the composition of the immune system is dynamically transformed
Dioncophyllines C2, D2, and F and related naphthylisoquinoline alkaloids from the Congolese liana <em>Ancistrocladus ileboensis</em> with potent... (Publications)
CEM/ADR5000. Moreover, the dioncophyllines 1, 3, and 7 showed high-and specific-activities against the malaria parasite Plasmodium falciparum.
More than seven decades of <em>Acta Tropica</em>: looking back to move into the future (Publications)
surveillance, control, and elimination of diseases that are intimately linked to poverty, such as malaria and neglected tropical diseases. In recent years, the scope of Acta Tropica was widening to target
Time to scale up molecular surveillance for anti-malarial drug resistance in sub-Saharan Africa (Publications)
emergence of resistance. However, molecular markers are not monitored systematically by national malaria control programmes, and are often assessed in research studies, but not in routine surveillance.
Variation in calculating and reporting antimalarial efficacy against<em> Plasmodium falciparum</em> in sub-Saharan Africa: a systematic review of... (Publications)
artemisinin-based combination therapies (ACTs), are critical tools in reducing the global burden of malaria, which is concentrated in sub-Saharan Africa. Performing and reporting antimalarial efficacy studies
Emergence of artemisinin-resistant <em>Plasmodium falciparum</em> with <em>kelch13 </em>C580Y mutations on the island of New Guinea (Publications)
nt Plasmodium falciparum carrying the C580Y mutation in the kelch13 gene is a growing threat to malaria elimination in Southeast Asia, but there is no evidence of their spread to other regions. We conducted
<em>P. falciparum</em> and <em>P. vivax</em> orthologous coiled-coil candidates for a potential cross-protective vaccine (Publications)
Over the last four decades, significant efforts have been invested to develop vaccines against malaria. Although most efforts are focused on the development of P. falciparum vaccines, the current availability
<em>In vitro</em> and<em> in vivo</em> activity of Solithromycin (CEM-101) against <em>Plasmodium</em> species (Publications)
the same dose required for artesunate or chloroquine to achieve 100% cure rates in this rodent malaria model. These promising in vitro and in vivo data support further investigations into the development
The antiprotozoal activity of methylated flavonoids from <em>Ageratum conyzoides</em> L (Publications)
against Leishmania donovani (Kala-Azar, IC(50)=3.4 microg/mL) as well as Plasmodium falciparum (Malaria tropica, IC(50)=8.0 microg/mL). In the current study, we sought for potentially active constituents